首页 | 本学科首页   官方微博 | 高级检索  
     

脐血巨核祖细胞的体外扩增
引用本文:Feng Y,Xiao ZJ,Xu SC,Lu SH,Liu B,Liu JH,Han ZC. 脐血巨核祖细胞的体外扩增[J]. 中国医学科学院学报, 2005, 27(2): 199-204
作者姓名:Feng Y  Xiao ZJ  Xu SC  Lu SH  Liu B  Liu JH  Han ZC
作者单位:中国医学科学院,中国协和医科大学,血液学研究所实验血液学国家重点实验室,天津,300020
基金项目:国家高技术研究发展计划(863计划),天津市科技攻关项目
摘    要:目的联合血小板生成素(TPO)、白细胞介素-11(IL-11)和肝素用脐血CD34 细胞定向扩增巨核祖细胞.方法采用免疫磁珠法(MACS)分选CD34 细胞,用TPO、IL-11和肝素定向扩增巨核祖细胞,巨核祖细胞集落分析(CFU-MK)测定巨核祖细胞扩增倍数,流式细胞术检测巨核祖细胞分化过程中不同细胞组群(CD34 、CD41a 、CD61 、CD34 CD41a 和CD41a CD61 )的变化,免疫组织化学染色(CD41a)和透射电镜观察巨核细胞形态及超微结构,血小板体外活化实验及非肥胖性糖尿病/严重联合免疫缺陷鼠异种体内移植实验评价扩增的巨核祖细胞功能.结果单用TPO 7 d时,CD34 CD41a 细胞扩增(4.0±1.7)倍;与IL-11联用后扩增到(10.5±4.8)倍;再加入肝素后扩增达(29.9±6.4)倍,TPO IL-11 肝素组扩增倍数为TPO组、TPO IL-11组的7.5、2.85倍,与两组相比差异均有显著性(P<0.05).TPO IL-11 肝素组巨核祖细胞中大集落(>50个细胞/集落)达(106.8±26.9)倍,较TPO、TPO IL-11组均有明显增加(P<0.05).将扩增第7天的巨核细胞静脉输注于经放射预处理的非肥胖性糖尿病/严重联合免疫缺陷鼠,可明显加速其血小板及白细胞的恢复并提高小鼠生存率.电镜显示扩增的巨核细胞有一定的界膜发育等成熟特征,体外血小板活化实验证实,扩增的巨核细胞在体外可产生血小板,有正常巨核细胞功能.结论TPO、IL-11和肝素组合的培养体系可有效扩增脐血巨核祖细胞.

关 键 词:脐血  巨核祖细胞  血小板生成素  白细胞介素-11  肝素
文章编号:1000-503X(2005)02-0199-06
修稿时间:2004-06-10

In vitro expansion of cord blood megakaryocyte progenitor
Feng Yi,Xiao Zhi-jian,Xu Shi-cai,Lu Shi-hong,Liu Bin,Liu Jin-hua,Han Zhong-chao. In vitro expansion of cord blood megakaryocyte progenitor[J]. Acta Academiae Medicinae Sinicae, 2005, 27(2): 199-204
Authors:Feng Yi  Xiao Zhi-jian  Xu Shi-cai  Lu Shi-hong  Liu Bin  Liu Jin-hua  Han Zhong-chao
Affiliation:National Key Laboratory of Experimental Hematology, Institute of Hematology, CAMS and PUMC, Tianjin 300020, China.
Abstract:OBJECTIVE: To expand cord blood megakaryocyte progenitor cells in vitro. METHODS: Cord blood CD34+ cells were selected by magnetic cell sorting (MACS), and thrombopoietin (TPO), interleukin-11 (IL-11), and heparin were used in the expansion system of megakaryocyte progenitor. The expansion efficiency was measured by fluorescence-activated cell sorting (FACS) using the megakaryocytic specific monoclonal antibodies (CD34+, CD41a+, CD61+, CD34+CD41a+, CD41a+CD61+) and colony-forming units-megakaryocyte (CFU-MK) analysis. The expanded megakaryocyte progenitor were determined by histochemistry staining using CD41a and the observation of the ultrastructure of megakaryocyte (MK) by electron microscopy. The megakaryocyte function were examined by the platelet activation in vitro and nonobese diabetic/severe combined immunodifficiency (NOD/SCID) mice transplantation in vivo. RESULTS: CD34+CD41a+ cells was expanded (4.0 +/- 1.7) folds on day 7 in TPO (50 ng/ml) group and (10.5 +/- 4.8) fold in TPO combined with IL-11 group; after heparin was joined in on day 0, a more significantly elevated expansion was found in the heparin, TPO, and IL-11 group [(29.9 +/- 6.4) folds than the above two groups; P < 0.05]. Meanwhile, the large CFU-MK colony (> 50 cells/colony) was (106.8 +/- 26.9) folds on day 7 (P < 0.05). The megakaryocyte expanding with TPO, IL-11 and heparin for 7 days in vitro transplanted the NOD/SCID mice fasten the recovery of platelet and white blood cell account and improved the survival. Megakaryocyte under culture displayed certain development of territories membrane. Platelet activation test comfirmed that the expanding megakaryocyte progenitor had the normal function. CONCLUSION: TPO, IL-11, and heparin combination system for ex vivo expansion is an effective expansion system of megakaryocyte progenitor.
Keywords:cord blood  megakaryocyte progenitor  thrombopoietin  interleukin-11  heparin  
本文献已被 CNKI 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号